ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics
CLPT Price/Volume Stats
| Current price | $5.33 | 52-week high | $10.80 |
| Prev. close | $5.39 | 52-week low | $4.05 |
| Day low | $5.25 | Volume | 129,000 |
| Day high | $5.49 | Avg. volume | 148,817 |
| 50-day MA | $6.66 | Dividend yield | N/A |
| 200-day MA | $6.17 | Market Cap | 144.28M |
CLPT Stock Price Chart Interactive Chart >
ClearPoint Neuro, Inc. (CLPT) Company Bio
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.
Latest CLPT News From Around the Web
Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.
Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 365%Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are... |
7 Solid Small-Caps for 2024 and BeyondSmall-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued |
Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 41%?Key Insights The projected fair value for ClearPoint Neuro is US$10.08 based on 2 Stage Free Cash Flow to Equity... |
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call TranscriptClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript November 9, 2023 ClearPoint Neuro, Inc. beats earnings expectations. Reported EPS is $-0.0002, expectations were $-0.25. Operator: Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call. Comments made on this call may include statements that are forward-looking within […] |
ClearPoint Neuro Reports Third Quarter 2023 ResultsBiologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8MSOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue |
CLPT Price Returns
| 1-mo | -23.86% |
| 3-mo | -29.03% |
| 6-mo | 9.90% |
| 1-year | -46.59% |
| 3-year | -69.51% |
| 5-year | 87.68% |
| YTD | -21.50% |
| 2023 | -19.83% |
| 2022 | -24.51% |
| 2021 | -29.39% |
| 2020 | 231.04% |
| 2019 | 205.73% |
Loading social stream, please wait...